This study showed that in the treatment of patients with metastatic and/or locally recurrent NPC, the median OS time was 29.9 months, and the 2-year OS rate was 62.9%.383 Importantly, the observed clinical benefits were directly related to the infusion of LMP2-specific T cells in CTL, as evidenced by a significant improvement in OS compared with patients who received CTL that lacked LMP2 specificity. This evidence concerns the gene PSMB9 and nasopharyngeal carcinoma.